In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma

被引:0
|
作者
Abas Sezer
Lejla Mahmutović
Betül Akçeşme
机构
[1] International University of Sarajevo,Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences
[2] University of Health Sciences,Department of Basic Medical Sciences, Division of Medical Biology
来源
关键词
Non-Hodgkin lymphoma; NF-ĸB signaling pathway; CBM complex; MALT1; Molecular docking; Polyphenols;
D O I
暂无
中图分类号
学科分类号
摘要
Non-Hodgkin lymphoma (NHL) is one of the most common cancer types. Deregulated signaling pathways can trigger certain NHL subtypes, including Diffuse Large B-cell lymphoma. NF-ĸB signaling pathway, which is responsible for the proliferation, growth, and survival of cells, has an essential role in lymphoma development. Although different signals control NF-ĸB activation in various lymphoid malignancies, the characteristic one is the CARD11-BCL10-MALT1 (CBM) complex. The CBM complex is responsible for the initiation of adaptive immune response. Our study is focused on the molecular docking of ten polyphenols as potential CARD11-BCL10-MALT1 complex inhibitors, essentially through MALT1 inhibition. Molecular docking was performed by Auto Dock Tools and AutoDock Vina tool, while SwissADME was used for drug-likeness and absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of the ligands. Out of 66 ligands that were used in this study, we selected and visualized five. Selection criteria were based on the binding energy score and position of the ligands on the used protein. 2D and 3D visualizations showed interactions of ligands with the protein. Five ligands are considered potential inhibitors of MALT1, thus affecting NF-ĸB signaling pathway. However, additional in vivo and in vitro studies are required to confirm their mechanism of inhibition.
引用
收藏
相关论文
共 50 条
  • [21] Ovarian non-Hodgkin lymphoma: case study
    Chasiotis, I.
    Lambropoulos, M.
    Elmazis, C.
    Vasileiou, M.
    Mpouklis, A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 32 (06) : 708 - 709
  • [22] Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
    Jiang, Vivian Changying
    Liu, Yang
    Lian, Junwei
    Huang, Shengjian
    Jordan, Alexa
    Cai, Qingsong
    Lin, Ruitao
    Yan, Fangfang
    McIntosh, Joseph
    Li, Yijing
    Che, Yuxuan
    Chen, Zhihong
    Vargas, Jovanny
    Badillo, Maria
    Bigcal, John Nelson
    Lee, Heng-Huan
    Wang, Wei
    Yao, Yixin
    Nie, Lei
    Flowers, Christopher R.
    Wang, Michael
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (03):
  • [23] Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
    Trkulja, Kyla L.
    Manji, Farheen
    Kuruvilla, John
    Laister, Rob C.
    BIOMOLECULES, 2023, 13 (01)
  • [24] Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin's lymphoma?
    Cohen, Melanie
    Graf, Solomon A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (06) : 637 - 640
  • [25] Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma
    Toni Valković
    Antica Duletić-Načinović
    Sanja Štifter
    Milena Hasan
    Ita Hadžisejdić
    David Zombori
    Blaženka Grahovac
    Nives Jonjić
    Clinical and Experimental Medicine, 2010, 10 : 229 - 235
  • [26] Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma
    Valkovic, Toni
    Duletic-Nacinovic, Antica
    Stifter, Sanja
    Hasan, Milena
    Hadzisejdic, Ita
    Zombori, David
    Grahovac, Blazenka
    Jonjic, Nives
    CLINICAL AND EXPERIMENTAL MEDICINE, 2010, 10 (04) : 229 - 235
  • [28] Expression profile of metalloproteinases and their inhibitors in Hodgkin's and non-Hodgkin's lymphoma.
    Thoms, C
    Gaiser, T
    Lange, K
    Merz, H
    Feller, AC
    LABORATORY INVESTIGATION, 2001, 81 (01) : 181A - 181A
  • [29] Expression of profile of metalloproteinases and their inhibitors in Hodgkin's and non-Hodgkin's lymphoma.
    Thorns, C
    Gaiser, T
    Lange, K
    Merz, H
    Feller, AC
    MODERN PATHOLOGY, 2001, 14 (01) : 181A - 181A
  • [30] Radioimmunotherapy - Potential as a therapeutic strategy in non-Hodgkin's lymphoma
    Wun, T
    Kwon, DS
    Tuscano, JM
    BIODRUGS, 2001, 15 (03) : 151 - 162